Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs.
Verschraegen
C F
CF
Section of Gynecologic Medical Therapeutics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 401, Houston, Texas 77030, USA. cverschr@mdanderson.org
Gilbert
B E
BE
Huaringa
A J
AJ
Newman
R
R
Harris
N
N
Leyva
F J
FJ
Keus
L
L
Campbell
K
K
Nelson-Taylor
T
T
Knight
V
V
D000328:Adult; D000336:Aerosols; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002166:Camptothecin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged
D000336:Aerosols; D000970:Antineoplastic Agents; D008081:Liposomes; C079905:rubitecan; D002166:Camptothecin